Your browser doesn't support javascript.
loading
Severe Late Toxicity After Adjuvant Breast Radiotherapy in a Patient with a Germline Ataxia Telangiectasia Mutated Gene: Future Treatment Decisions.
Dosani, Maryam; Schrader, Kasmintan A; Nichol, Alan; Sun, Sophie; Shenkier, Tamara; Lohn, Zoe; Aubertin, Gudrun; Tyldesley, Scott.
Afiliação
  • Dosani M; Radiation Oncology, BC Cancer Agency, Vancouver Centre.
  • Schrader KA; Hereditary Cancer Program, BC Cancer Agency, Vancouver Centre.
  • Nichol A; Radiation Oncology, BC Cancer Agency, Vancouver Centre.
  • Sun S; Hereditary Cancer Program, BC Cancer Agency, Vancouver Centre.
  • Shenkier T; Medical Oncology, BC Cancer Agency, Vancouver Centre.
  • Lohn Z; Hereditary Cancer Program, BC Cancer Agency, Vancouver Centre.
  • Aubertin G; Hereditary Cancer Program, BC Cancer Agency, Vancouver Centre.
  • Tyldesley S; Radiation Oncology, BC Cancer Agency, Vancouver Centre.
Cureus ; 9(7): e1458, 2017 Jul 11.
Article em En | MEDLINE | ID: mdl-28929041
ABSTRACT
Ataxia telangiectasia mutated (ATM) gene mutations may confer increased sensitivity to ionizing radiation and increased risk of late toxicity for cancer patients. We present the case of a 55-year-old female treated with adjuvant breast and regional nodal radiation following lumpectomy and axillary lymph node dissection for stage II invasive ductal carcinoma of the breast. She developed severe telangiectasia, fibrosis, induration, chest wall pain (with evidence of rib fractures on imaging), and painful limitation in her range of motion at the shoulder. She was subsequently found to have a likely pathogenic germline ATM gene mutation. At relapse, she elected to pursue systemic therapy alone for intracranial metastases.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article